CN108300779A - A kind of kit and method for predicting the SNP site of leflunomide curative effect of medication - Google Patents
A kind of kit and method for predicting the SNP site of leflunomide curative effect of medication Download PDFInfo
- Publication number
- CN108300779A CN108300779A CN201810111993.8A CN201810111993A CN108300779A CN 108300779 A CN108300779 A CN 108300779A CN 201810111993 A CN201810111993 A CN 201810111993A CN 108300779 A CN108300779 A CN 108300779A
- Authority
- CN
- China
- Prior art keywords
- leflunomide
- medication
- curative effect
- risk
- predicting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A kind of method and kit for predicting the SNP site of leflunomide curative effect of medication and adverse reaction, the present invention relates to molecular biology and medical domain, mononucleotide polymorphism site (SNP) genotype for detection leflunomide curative effect of medication and the closely related DHODH genes and CYP1A2 genes of adverse reaction risk assesses curative effect and adverse reaction risk of the leflunomide in rheumatoid arthritis and other diseases use, the present invention provides a kind of systems for predicting the SNP site of leflunomide curative effect of medication and risk, the forecasting system includes distinguished sequence primer, specific probe and reporter probe.The beneficial effects of the present invention are：Provide the primer, probe and reporter probe of distinguished sequence, innovatively the gene loci of one group of leflunomide curative effect of medication and adverse reaction risk is detected, prediction rheumatoid arthritis and other patients take curative effect and the risk of adverse reaction after leflunomide, are conducive to the accurate medication of patient.
Description
Technical field
The present invention relates to molecular biology and medical domain, and more specifically, the present invention relates to one group of leflunomide drugs to treat
The system and kit of effect and adverse reaction risk SNP site, by detecting leflunomide curative effect of medication and adverse reaction simultaneously
Mononucleotide polymorphism site (SNP) genotype of the closely related DHODH genes of risk and CYP1A2 genes carrys out fluorine to assess
Curative effects and adverse reaction risk of the meter Te in rheumatoid arthritis and other diseases use.
Background technology
Leflunomide is a kind of slow effect antirheumatic object (DMARD) being directed to rheumatoid arthrosis (RA).Previous faces
Bed experiment confirm leflunomide treatment patient in have 30-50% reach disease activity decline 20% (ACR20), in addition with first
Curative effect is also very notable when aminopterin is combined.But still have quite a few patient reactionless to its, up to 40% patient in addition
It must discontinue medication because of toxicity；There is gastrointestinal toxicity (diarrhea, nausea and vomiting) in the patient of about 20-30%, this is often
Come across medication early stage and may spontaneous remission after long-term use.Patient invalid traditional DMARDs would generally be considered
Biological DMARDs, but biology DMARDs may increase the risk of certain types of cancer and infection and expensive.So using compared with
It is still a kind of preferable selection for economy and drug (such as leflunomide) that recurrence rate can be reduced.Therefore, prediction patient is to coming
How quite important fluorine rice spy reaction is, but the effect of usual clinical judgment leflunomide needs 3 months, and and drug response
Relevant hereditary feature contributes to early stage to be prejudged before the treatment starts, to help clinician to determine therapeutic choice rapidly.
The mechanism of action of leflunomide relates generally to the inhibition to enzyme DHODH, and DHODH extremely closes the de novo formation of pyrimidine
It is important.By inhibiting the synthesis of pyrimidine, the proliferation of T cell is suppressed, and the gene of encoding D HODH is located at No. 16 chromosome
On long-armed, length about 16kbp.Pawlik et al. analyzes the non-synonymous SNP in first exon of DHODH genes
(rs3213422), as a result, it has been found that C allele is related to the enhancing of leflunomide therapeutic response, at the same C allele also with treatment
Risk of toxicity decline it is related.
Leflunomide is a kind of pro-drug, in vivo rapidly by conversion teriflunomide (active metabolite).Cell color
Plain P-450 enzymes CYP1A2 is responsible for leflunomide being metabolized as teriflunomide, research shows that the gene pleiomorphism of CYP1A2 may be with
The toxicity of leflunomide increases and the variation of plasma concentration is related.There is research to confirm that the A allele toxicity of CYP1A2C734A is anti-
The risk answered increases by 9.7 times (P=0.002, OR=9.708,95%CI=2.276,41.403).
Invention content
It is mentioned above in order to solve the problems, such as, the present invention provides one kind can predict patient to leflunomide reaction how
System, kit and method.
A kind of system for predicting the SNP site of leflunomide curative effect of medication and risk, the kit include：
Following distinguished sequence primer：
Following Sequence-specific probe：
Following sequence reporter probe：
A kind of kit for predicting the genotype of leflunomide curative effect of medication and risk, the kit include
Above-mentioned distinguished sequence primer, probe and reporter probe.
A method of the SNP site for predicting leflunomide curative effect of medication and risk, the method include as follows
Step：PCR reactions are carried out first, realize amplification；Multiple OLA reactions, label and connection are carried out again；Then hybridization reaction is carried out,
Finally carry out the analysis of genotype.
Preferably, the PCR reaction systems are as follows：2x qiagen Hotstar MM 5ul, primer mix1ul,
DNA sample 2ul, aqua sterilisa 2ul；PCR reaction conditions be 95 DEG C, 15min, carry out 30 cycle 94 DEG C, 30 seconds, 60 DEG C, 30
Second, 72 DEG C, 30 seconds；72 DEG C, 7 minutes, 4 DEG C of maintenances.
Preferably, OLA reactions are as follows：2xOLA master mix are prepared, OLA master mix and PCR is anti-
It answers product to mix, reaction is attached after mixing.
Preferably, preparing 2xOLA master mix includes：10x Taq Ligase buffer 2ul,40000U/ml
Taq DNA Ligase 0.25ul, wild-type probe mix 1ul, saltant type probe mix 2ul, deionized water 4.75ul.
Preferably, connection reaction condition is as follows：96 DEG C of 2min, the 94 DEG C of 15s, 37 DEG C of 1min of 30 cycles；4 DEG C of maintenances.
Preferably, the washing procedure process of hybridization reaction is as follows：The magnetic bead of corresponding reporter probe is selected, is resuspended, then
Each magnetic bead is mixed, dilution is up to 100u/ul and magnetic is added after mixing with 2X Tm hybridization buffer
In pearl mixture to every hole, 1-5ul OLAreaction and 25ul dH are added2O carries out PCR reactions to each hole：96℃
90s, 37 DEG C of 30min, siphons away supernatant, magnetic bead is resuspended with 1x Tm hybridization buffer, magnetically attractive 30-60s inhales again
Supernatant is walked, repeats that magnetic bead is resuspended with 1x Tm hybridization buffer, magnetically attractive 30-60s siphons away supernatant for the third time, uses
Magnetic bead is resuspended in 1x Tm hybridization buffer, and 15min is incubated at 37 DEG C, and 50ul reaction products are added to LUMINEX
Middle analysis.
Preferably, the not washing process of hybridization reaction is as follows：1, magnetic bead is selected, and is resuspended；2, each magnetic bead is mixed, and
It is diluted to 100u/ul, with 2X Tm hybridization buffer, oscillation mixing；3, magnetic bead mix is added to every hole
In；4, it adds in sample to every hole；5, PCR reactions are carried out：96 DEG C of 90s, 37 DEG C of 30min；6, prepare 6ug/ml SAPE in 1x
hybridization buffer；7,100ul SAPEmix, mixing are added；8,37 DEG C of incubation 15min；9,100ul to 37 is added
DEG C luminex in analyze.
The beneficial effects of the present invention are：The primer, probe and reporter probe for providing distinguished sequence, innovatively to one
Group leflunomide curative effect of medication and the gene loci of adverse reaction risk are detected, and predict rheumatoid arthritis and other patients
Curative effect and the risk of adverse reaction after leflunomide are taken, the accurate medication of patient is conducive to.
Specific implementation mode
The present invention provides a kind of kit, and kit is directed in human genome DNA leflunomide curative effect of medication and bad
React the gene loci of risk, i.e. DHODH (19C>A) i.e. rs3213422 and CYP1A2 (734C>A) i.e. rs762551.Design
Specific primer and wild type/saltant type probe, the MagPlex-TAG magnetic beads of reporter probe corresponding to coupling hybridize anti-
It answers, is detected on 200 instruments of luminex by chromogenic reaction.Pass through each SNP site of reading interpretation to signal value
Base type judged.
Specific primer sequences involved in kit are as follows：
The specific probe sequence being related to is as follows：
The reporter probe sequence being related to is as follows：
Its detection process is as follows：
(1) 2 SNP site carries out PCR reactions in same pipe, and the system of reaction is 10 μ l of total volume, including 2x qiagen
Hotstar MM 5ul, primer mix 1ul, DNA sample 2ul, aqua sterilisa 2ul.
It is reacted in ABI9700 type PCR amplification instruments, reaction condition is 95 DEG C, 15min, carries out the 94 of 30 cycles
DEG C, 30 seconds, 60 DEG C, 30 seconds, 72 DEG C, 30 seconds；72 DEG C, 7 minutes, 4 DEG C of maintenances.
(2) multiple OLA reactions：Prepare 2xOLA master mix：10x Taq Ligase buffer 2ul,Taq DNA
Ligase (40,000U/ml) 0.25ul, wild-type probe mix (100nM each) 1ul, saltant type probe mix (2.5uM
Each) 2ul, deionized water 4.75ul.OLA master mix are mixed with reaction product：2xOLA master mix 10ul,
The PCR product 5ul of amplification, sterile deionized water 5ul.Piping and druming mixing up and down covers reaction tube, expand in ABI9700 types PCR
Increase and connects reaction on instrument.96 DEG C of 2min, the 94 DEG C of 15s, 37 DEG C of 1min of 30 cycles；4 DEG C of maintenances.
(3) hybridization reaction：The MagPlex-TAG magnetic beads of corresponding reporter probe are selected, and are resuspended.Each magnetic bead is mixed,
And it is diluted to 100u/ul, with 2X Tm hybridization buffer, oscillation mixing 20s.25ul magnetic bead mix is added
Into every hole.(2500 pearls/each reaction should be provided).1-5ul OLA reaction and 25ul dH2O are added to every
A hole.The volume for adjusting H2O, makes total volume close to 50ul.It closes the lid, carries out PCR reactions：96℃90s,37℃30min.It puts
The 30s-60s in magnetic board, makes magnetic bead be sucked.Supernatant carefully is siphoned away, does not siphon away magnetic bead.With 1x Tm hybridization
MagPlex-TAG magnetic beads, magnetically attractive 30-60s is resuspended in buffer 75ul.Supernatant carefully is siphoned away, does not siphon away magnetic bead.Repetition 1x
MagPlex-TAG magnetic beads, magnetically attractive 30-60s is resuspended in Tm hybridization buffer 75ul.Carefully siphon away supernatant.With
75ul 1x Tm hybridization buffer (including 2-8ug/ml SAPE), are resuspended magnetic bead, 15min are incubated at 37 DEG C.
In 37 DEG C, it is added in 50ul reaction products to LUMINEX and analyzes.
(4) interpretation of result
It is compareed by plasmid and water, obtains background signal, when detecting sample results, after subtracting background, numerical value is more than 200
For positive reaction.
2 SNP types can be provided in examining report as a result, reference gene is wild type gene.Detect DHODH (19C>A)
The corresponding result of gene rs3213422 saltant types is shown as AA, and the corresponding result of heterozygous is shown as CA, the corresponding knot of wild type
Fruit is shown as CC.CYP1A2(734C>A) the corresponding result of gene rs762551 saltant types is shown as AA, the corresponding knot of heterozygous
Fruit is shown as AC, and the corresponding result of wild type is shown as CC.
Sequence table
<110>Guangzhou and health medical technology Co., Ltd
<120>A kind of kit and method for predicting the SNP site of leflunomide curative effect of medication
<130> PJ1810004.06
<160> 10
<170> SIPOSequenceListing 1.0
<210> 1
<211> 18
<212> DNA
<213>Artificial sequence (" artificial sequence ")
<400> 1
gccaccatct cctccaat 18
<210> 2
<211> 19
<212> DNA
<213>Artificial sequence (" artificial sequence ")
<400> 2
gcggtcatgt gttcactaa 19
<210> 3
<211> 17
<212> DNA
<213>Artificial sequence (" artificial sequence ")
<400> 3
gggcacttcg accctta 17
<210> 4
<211> 18
<212> DNA
<213>Artificial sequence (" artificial sequence ")
<400> 4
ctgatagtgc tcctggac 18
<210> 5
<211> 40
<212> DNA
<213>Artificial sequence (" artificial sequence ")
<400> 5
attcaatact atctaacact tactgcgtgg agacacctgc 40
<210> 6
<211> 40
<212> DNA
<213>Artificial sequence (" artificial sequence ")
<400> 6
acttacaata actactaata ctctgcgtgg agacacctga 40
<210> 7
<211> 41
<212> DNA
<213>Artificial sequence (" artificial sequence ")
<400> 7
tcatcacttt ctttacttta cattcccatc cttcgctacc a 41
<210> 8
<211> 41
<212> DNA
<213>Artificial sequence (" artificial sequence ")
<400> 8
aatttcttct ctttctttca caatcccatc cttcgctacc t 41
<210> 9
<211> 18
<212> DNA
<213>Artificial sequence (" artificial sequence ")
<400> 9
aagtgagtcc cgcgagtg 18
<210> 10
<211> 16
<212> DNA
<213>Artificial sequence (" artificial sequence ")
<400> 10
gcctaaccct gccctg 16
Claims (9)
1. a kind of kit for predicting the SNP site of leflunomide curative effect of medication and risk, which is characterized in that the examination
Agent box includes：
Following distinguished sequence primer：
Following Sequence-specific probe：
Following sequence reporter probe：
2. a kind of kit for predicting the genotype of leflunomide curative effect of medication and risk, which is characterized in that the examination
Agent box includes any one or several combinations of primer, specific probe and reporter probe as described in claim 1.
3. a kind of method for predicting the SNP site of leflunomide curative effect of medication and risk, which is characterized in that the method
Include the following steps：PCR reactions are carried out first, realize amplification；Multiple OLA reactions, label and connection are carried out again；Then it carries out miscellaneous
Reaction is handed over, the analysis of genotype is finally carried out.
4. the method as claimed in claim 3 for predicting the SNP site of leflunomide curative effect of medication and risk, feature exists
In the PCR reaction systems are as follows：2x qiagen Hotstar MM 5ul, primer mix 1ul, DNA sample 2ul,
Aqua sterilisa 2ul；PCR reaction conditions be 95 DEG C, 15min, carry out 30 cycle 94 DEG C, 30 seconds, 60 DEG C, 30 seconds, 72 DEG C, 30
Second；72 DEG C, 7 minutes, 4 DEG C of maintenances.
5. the method as claimed in claim 4 for predicting the SNP site of leflunomide curative effect of medication and risk, feature exists
In preparing 2xOLA master mix includes：The Taq DNA of 10x Taq Ligase buffer 2ul, 40000U/ml
Ligase 0.25ul, wild-type probe mix 1ul, saltant type probe mix 2ul, deionized water 4.75ul.
6. the method as claimed in claim 3 for predicting the SNP site of leflunomide curative effect of medication and risk, feature exists
In OLA reactions are as follows：2xOLA master mix are prepared, OLA master mix are mixed with PCR reaction products,
Reaction is attached after mixing.
7. the method as claimed in claim 3 for predicting the SNP site of leflunomide curative effect of medication and risk, feature exists
In connection reaction condition is as follows：96 DEG C of 2min, the 94 DEG C of 15s, 37 DEG C of 1min of 30 cycles；4 DEG C of maintenances.
8. the side of the SNP site genotype detection of a kind of detection leflunomide curative effect of medication as claimed in claim 3 and risk
Method, which is characterized in that the washing procedure process of hybridization reaction is as follows：The magnetic bead of corresponding reporter probe is selected, is resuspended, then will
Each magnetic bead mixes, and dilution is up to 100u/ul and magnetic bead is added after mixing with 2X Tm hybridization buffer
In mixture to every hole, 1-5ul OLA reaction and 25ul dH are added2O carries out PCR reactions to each hole：96℃90s,
37 DEG C of 30min, siphon away supernatant, magnetic bead are resuspended with 1x Tm hybridization buffer, magnetically attractive 30-60s is siphoned away again
Clearly, it repeats that magnetic bead is resuspended with 1x Tm hybridization buffer, magnetically attractive 30-60s siphons away supernatant for the third time, with 1x Tm
Magnetic bead is resuspended in hybridization buffer, and 15min is incubated at 37 DEG C, is added in 50ul reaction products to LUMINEX and analyzes.
9. the side of the SNP site genotype detection of a kind of detection leflunomide curative effect of medication as claimed in claim 3 and risk
Method, which is characterized in that the not washing process of hybridization reaction is as follows：1, magnetic bead is selected, and is resuspended；2, each magnetic bead is mixed, and
It is diluted to 100u/ul, with 2X Tm hybridization buffer, oscillation mixing；3, magnetic bead mix is added to every hole
In；4, it adds in sample to every hole；5, PCR reactions are carried out：96 DEG C of 90s, 37 DEG C of 30min；6, prepare 6ug/ml SAPE in 1x
hybridization buffer；7,100ul SAPE mix, mixing are added；8,37 DEG C of incubation 15min；9,100ul is added extremely
It is analyzed in 37 DEG C of luminex.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810111993.8A CN108300779A (en) | 2018-02-05 | 2018-02-05 | A kind of kit and method for predicting the SNP site of leflunomide curative effect of medication |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810111993.8A CN108300779A (en) | 2018-02-05 | 2018-02-05 | A kind of kit and method for predicting the SNP site of leflunomide curative effect of medication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108300779A true CN108300779A (en) | 2018-07-20 |
Family
ID=62864248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810111993.8A Pending CN108300779A (en) | 2018-02-05 | 2018-02-05 | A kind of kit and method for predicting the SNP site of leflunomide curative effect of medication |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108300779A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101711286A (en) * | 2007-04-02 | 2010-05-19 | 健泰科生物技术公司 | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
| CN101748196A (en) * | 2008-12-11 | 2010-06-23 | 上海人类基因组研究中心 | SNP rs762551 of CYP1A2 gene and application thereof in relevant drug metabolism activity detection |
| CN105586389A (en) * | 2014-10-21 | 2016-05-18 | 天津华大基因科技有限公司 | Kit and application thereof in detection on hereditary bone disease genes |
| CN105803054A (en) * | 2014-12-31 | 2016-07-27 | 天津华大基因科技有限公司 | Kit and use thereof in detection of orofacial clefts related genes |
| CN106222281A (en) * | 2016-08-10 | 2016-12-14 | 中南大学湘雅三医院 | Test kit, application and method of based on the gene pleiomorphism accurate medication of guiding children patient |
| CN107644087A (en) * | 2017-09-25 | 2018-01-30 | 云健康基因科技（上海）有限公司 | Coffee beverage recommends method, commending system and computer-readable recording medium |
-
2018
- 2018-02-05 CN CN201810111993.8A patent/CN108300779A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101711286A (en) * | 2007-04-02 | 2010-05-19 | 健泰科生物技术公司 | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
| CN101748196A (en) * | 2008-12-11 | 2010-06-23 | 上海人类基因组研究中心 | SNP rs762551 of CYP1A2 gene and application thereof in relevant drug metabolism activity detection |
| CN105586389A (en) * | 2014-10-21 | 2016-05-18 | 天津华大基因科技有限公司 | Kit and application thereof in detection on hereditary bone disease genes |
| CN105803054A (en) * | 2014-12-31 | 2016-07-27 | 天津华大基因科技有限公司 | Kit and use thereof in detection of orofacial clefts related genes |
| CN106222281A (en) * | 2016-08-10 | 2016-12-14 | 中南大学湘雅三医院 | Test kit, application and method of based on the gene pleiomorphism accurate medication of guiding children patient |
| CN107644087A (en) * | 2017-09-25 | 2018-01-30 | 云健康基因科技（上海）有限公司 | Coffee beverage recommends method, commending system and computer-readable recording medium |
Non-Patent Citations (5)
| Title |
|---|
| CHRISTOPH SACHSE等: "Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2gene tested with caffeine", 《BR J CLIN PHARMACOL》 * |
| MICHAEL D WIESE等: "Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis", 《ARTHRITIS RESEARCH & THERAPY》 * |
| P BOHANEC GRABAR等: "Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis", 《ANN RHEUM DIS》 * |
| PAWLIK A等: "The effect of exon (19C＞A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide", 《PHARMACOGENOMICS》 * |
| PETRA BOHANEC GRABAR等: "Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients", 《EUR J CLIN PHARMACOL》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160222468A1 (en) | Diagnosis, prognosis and treatment of glioblastoma multiforme | |
| US10724099B2 (en) | Multiplex methods to assay mixed cell populations simultaneously | |
| CA2546171A1 (en) | Method of detecting mutations associated with thrombosis | |
| US10260102B2 (en) | Methods and compositions for detecting mutation in the human EZH2 gene | |
| KR101992786B1 (en) | Method for providing information of prediction and diagnosis of obesity using methylation level of CYP2E1 gene and composition therefor | |
| Elingarami et al. | NEIL-2 single nucleotide polymorphism genotyping using single base extension on core–shell Fe3O4@ SiO2@ Au magnetic nanoparticles and association of the genotypes with gastric cancer risk in Northern Jiangsu (China) | |
| CN109952383A (en) | For predicting the active method and composition of Enzastaurin | |
| CN106834519A (en) | A kind of primer of TaqMan MGB sonde methods detection mankind's ALDH2 gene pleiomorphisms and its application | |
| CN108004307A (en) | A kind of method and kit of the detection of glucocorticoid outcome prediction SNP site | |
| KR101992792B1 (en) | Method for providing information of prediction and diagnosis of obesity using methylation level of AKR1E2 gene and composition therefor | |
| US20060073479A1 (en) | Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness | |
| EP1585433A2 (en) | Detection methods | |
| WO2010020619A2 (en) | Susceptibility to dasatinib | |
| Kaneva et al. | Detection of mitochondrial DNA variants at low level heteroplasmy in pediatric CNS and extra-CNS solid tumors with three different enrichment methods | |
| CN108300779A (en) | A kind of kit and method for predicting the SNP site of leflunomide curative effect of medication | |
| JP2020120625A (en) | Risk assessment method for non-alcoholic liver disease using single nucleotide polymorphism | |
| US11384385B2 (en) | Method for predicting therapeutic effects of irinotecan, and kit for same | |
| CN108004305A (en) | A kind of method and kit of the SNP site genotype for detecting methotrexate (MTX) curative effect | |
| CN107988335B (en) | Loop-shaped LNA probe for point mutation detection and application thereof | |
| EP2148943B1 (en) | Methods for assessing and treating ulcerative colitis and related disorders using a 19 gene panel | |
| CN108004306A (en) | It is a kind of to CTX adverse drug reaction SNP site genotype detection methods and kit | |
| CN107760778A (en) | A kind of detection method and its kit that genotype detection is carried out to CYP2C9 sites | |
| CN107574239A (en) | A kind of detection method and kit for detecting sulphur purine medicine SNP site genotype | |
| JP4549297B2 (en) | Method and kit for predicting side effects of paclitaxel therapy | |
| CN111670256B (en) | Single nucleotide polymorphism site related to main adverse cardiovascular event and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180720 |